Skip to content

TESTING -ON Post-Trial ObservatioNal Cohort Study

ESRD | Kidney Diseases | IgA Nephropathy | Glomerulonephritis

The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1) Only participants who were randomised into the TESTING trial

Exclusion Criteria

1. Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
2. Participants who died during the TESTING trial
3. Participants who had withdrawn their consent during the TESTING trial
4. Participants who are unable to provide consent for some other reason

Study Location

St Pauls Hospital
St Pauls Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Toronto General Hospital,
Toronto General Hospital,
Toronto, Ontario
Canada

Contact Study Team

University of Alberta Hospitals
University of Alberta Hospitals
Edmonton, Alberta
Canada

Contact Study Team

Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

St. Joseph's Healthcare
St. Joseph's Healthcare
Hamiliton, Ontario
Canada

Contact Study Team

Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-Rosemont
Montreal, Quebec
Canada

Contact Study Team

University of Calgary/Alberta Health Services
University of Calgary/Alberta Health Services
Calgary, Alberta
Canada

Contact Study Team

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Study Sponsored By
The George Institute
Participants Required
More Information
Study ID: NCT05434325